Data |  | All patients (n = 3075) n (%) | STAS | p | |
---|---|---|---|---|---|
Present (n = 617) | Absent (n = 2458) | ||||
n (%) | n (%) | ||||
PD1 tumor cell |  < 1% | 2868 (98.86) | 573 (19.98) | 2295 (80.02) | 0.661 |
 ≥ 1% | 33 (1.14) | 5 (15.15) | 28 (84.85) | ||
PD1 stromal cell |  < 1% | 510 (17.61) | 54 (10.59) | 456 (89.41) |  < 0.001 |
1–5% | 1206 (41.64) | 218 (18.08) | 988 (81.92) | ||
5–10% | 697 (24.07) | 166 (23.82) | 531 (76.18) | ||
 ≥ 10% | 483 (16.68) | 140 (28.99) | 343 (71.01) | ||
PD-L1(SP28-8) tumor cell |  < 1% | 1879 (85.76) | 311 (16.55) | 1568 (83.45) |  < 0.001 |
1–5% | 86 (3.93) | 31 (36.05) | 55 (63.95) | ||
5–10% | 48 (2.19) | 18 (37.50) | 30 (62.50) | ||
 ≥ 10% | 178 (8.12) | 65 (36.52) | 113 (63.48) | ||
PD-L1(SP28-8) stromal cell |  < 1% | 718 (33.04) | 108 (15.04) | 610 (84.96) |  < 0.001 |
1–5% | 353 (16.24) | 94 (26.63) | 259 (73.37) | ||
5–10% | 139 (6.40) | 53 (38.13) | 86 (61.87) | ||
 ≥ 10% | 963 (44.32) | 164 (17.03) | 799 (82.97) | ||
PD-L1(SP142) tumor cell |  < 1% | 1588 (78.34) | 255 (16.06) | 1333 (83.94) |  < 0.001 |
1–5% | 102 (5.03) | 32 (31.37) | 70 (68.63) | ||
5–10% | 67 (3.31) | 28 (41.79) | 39 (58.21) | ||
 ≥ 10% | 270 (13.32) | 106 (39.26) | 164 (60.74) | ||
PD-L1(SP142) stromal cell |  < 1% | 423 (20.91) | 49 (11.58) | 374 (88.42) |  < 0.001 |
1–5% | 365 (18.04) | 88 (24.11) | 277 (75.89) | ||
5–0% | 245 (12.11) | 85 (34.69) | 160 (65.31) | ||
 ≥ 10% | 990 (48.94) | 196 (19.80) | 794 (80.20) |